Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter controlled study of clofazimine for drug-resistant tuberculosis
ChiCTR1800014800Phase 4Completed
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clofazimine in multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) (4 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Sputum conversion rate at end of treatment. Started Dec 2009; status: completed.
02
Drugs
clofazimine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)Extensively drug-resistant tuberculosis (XDR-TB)
Beyond the preview
Go deeper on ChiCTR1800014800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014800.